Prospective, Randomized, Open, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of the MON4STRAT Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Adult Patients With Severe Gram-Negative Lower Respiratory Tract Infection MON4STRAT Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lower Respiratory Tract Infection
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- Enrollment
- 7
- Locations
- 3
- Primary Endpoint
- To document the superiority of the MON4STRAT approach for reaching and maintaining a meropenem pre-determined PK-PD target when compared to conventional therapies.
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
Antibacterial drugs are facing increasing limitations in terms of effectiveness due to emergence resistance. Improved antibacterial drug monitoring approaches are particularly needed in nosocomial infections occurring in ICU patients, including ventilator-associated pneumonia and ventilator-associated tracheobronchitis, where decreased susceptibility of the etiological organisms is observed worldwide and pharmacokinetic alterations frequently observed.
No routine drug monitoring is available for betalactams at the point of care in a useful time frame (i.e., within a few hours after having collected the blood specimens).
The purpose of this study is to compare MON4STRAT approach for reaching and maintaining a meropenem pre-determined PK-PD target when compared to conventional meropenem dose.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males and non-pregnant, non-lactating females, 18 years of age or older
- •Currently intubated and mechanically-ventilated subjects in the ICU
- •Suspicion of lower respiratory tract infection
- •Presence of Gram-negative organism(s) by Gram stain OR by culture of pre-therapy respiratory specimen (eg, endotracheal aspirate \[ETA\], bronchoalveolar lavage \[BAL\], or mini-BAL) OR previous colonization 48 h before screening.
- •Initial empiric antimicrobial meropenem regimen
- •At least two risk factors for multidrug-resistant organisms
- •Provision of written informed consent by the subject or a family member or a close relative or waiver of consent.
Exclusion Criteria
- •Subjects who have received antibiotic therapy for Gram-negative LRT infection for ≥ 36 hours at the time of randomization
- •Subjects with known or suspected type 1 hypersensitivity to beta-lactam and/or cephalosporin
- •Subjects taking valproic acid for a seizure disorder
- •Subjects who have had a left hemisphere stroke within five days and there is an increased risk of fatal brain oedema
- •Subjects who have cystic fibrosis, human immunodeficiency virus (HIV) infection with CD4 count \<100 cell/mm3 or invasive fungal infection of the lung
- •Neutropenia (ANC \< 103 neutrophils/mm3)
- •Bone marrow transplant.
- •Subjects who have been on mechanical ventilation for \>28 days
Outcomes
Primary Outcomes
To document the superiority of the MON4STRAT approach for reaching and maintaining a meropenem pre-determined PK-PD target when compared to conventional therapies.
Time Frame: During meropenem treatment: Day1 to Day 7
The proportion of time from day 1 after randomization to end of therapy (EOT) in which the free meropenem trough concentration in serum was maintained above 8 mg/L or above 4 x MIC if antibiotic MIC \> 2 and ≤ 8 mg/L, without exceeding 140 mg/L at peak level, as determined by a method of reference (HPLC).
Secondary Outcomes
- ICU and hospital length of stay(Up to day 28)
- Number of mechanical ventilation-free days, defined as the number of days of unassisted breathing(Up to day 28)
- Time to LRT bacterial eradication, as assessed by follow-up cultures of ETA(Days 3, 5, 7 of treatment and at the end of treatment (EOT) visit)
- Clinical and microbiological response rates(Test of cure (TOC) visit (7 to 10 days after last study drug infusion))
- All-cause mortality(Day 14 and day 28)